Explanipedia

Oritavancin for Treatment of Osteomyelitis: A Systematic Review and Meta‐Analysis of Observational Studies Open

David Klimpl, Scott W. Mueller, Taylor Morrisette, Daniel B. Chastain, Kyle C. Molina · 2025

Background Osteomyelitis (OM) is a complex inflammatory bone infection typically requiring prolonged antibiotic therapy. Oritavancin (ORI), a long‐acting lipoglycopeptide with activity against biofilm‐embedded pathogens, has emerged as a p…

Association of remdesivir treatment with long-term mortality after COVID-19 hospitalization Open

Trisha Agarwal, Laurel Beaty, Nichole E. Carlson, Tellen D. Bennett, Lindsey E. Fish , et al. · 2025

Correction: Clinical Outcomes of Eravacycline in Patients Treated for Stenotrophomonas maltophilia Infections Open

Mohammed Al Musawa, Ashlan J. Kunz Coyne, Sara Alosaimy, Kristen Lucas, Melanie Rae Schrack , et al. · 2025

Eravacycline use in immunocompromised patients: multicenter evaluation of timely versus late initiation on clinical outcomes Open

Ashlan J. Kunz Coyne, Sara Alosaimy, Kristen Lucas, Taylor Morrisette, Kyle C. Molina , et al. · 2025

Infections from multidrug-resistant (MDR) bacteria lead to worse outcomes in immunocompromised patients. Eravacycline (ERV) is effective against MDR gram-negative and gram-positive bacteria, but its effects in immunocompromised populations…

Implementation of an Online Drug–Drug Interaction Screener for the STRIVE Ensitrelvir Trial for COVID-19 Open

Joshua P Havens, Nayon Kang, Lucy Chung, Courtney V. Fletcher, Page Crew , et al. · 2025

Background Ensitrelvir is an antiviral agent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with associated drug–drug interactions (DDIs) through CYP3A, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), …

Clinical Outcomes of Eravacycline in Patients Treated for Stenotrophomonas maltophilia Infections Open

Mohammed Al Musawa, Ashlan J. Kunz Coyne, Sara Alosaimy, Kristen Lucas, Melanie Rae Schrack , et al. · 2025

P-887. Evaluation of ceftriaxone and cefotaxime as surrogate markers for oral second and third generation cephalosporins in Escherichia coli strains from blood Open

Tho H Pham, Kyle C. Molina, Vanthida Huang · 2025

Background Oral second- and third-generation cephalosporins are increasingly being utilized as oral transitional therapy for Escherichia coli bloodstream infections due to resistance or intolerance to other classes. However, most automated…

A Machine Learning Method for Allocating Scarce COVID-19 Monoclonal Antibodies Open

Mengli Xiao, Kyle C. Molina, Neil R. Aggarwal, Laurel Beaty, Tellen D. Bennett , et al. · 2024

Importance During the COVID-19 pandemic, the effective distribution of limited treatments became a crucial policy goal. Yet, limited research exists using electronic health record data and machine learning techniques, such as policy learni…

Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5 Open

Kyle C. Molina, Brandon Webb, Victoria Kennerley, Laurel Beaty, Tellen D. Bennett , et al. · 2024

Evaluation of Oral Amoxicillin/Clavulanate for Urinary Tract Infections Caused by Ceftriaxone Non-Susceptible Enterobacterales Open

Madison E. Salam, Meghan N. Jeffres, Kyle C. Molina, Matthew A. Miller, Misha Huang , et al. · 2024

Urinary tract infections (UTIs) are one of the most common infections and are frequently caused by Gram-negative organisms. The rise of resistant isolates has prompted evaluation of alternative therapies, including amoxicillin-clavulanate …

Bone and Skin/Subcutaneous Tissue Concentrations of Cefiderocol During Treatment of Extensively Drug-Resistant Pseudomonas aeruginosa Open

Scott W. Mueller, Kyle C. Molina, Brittany Blass, Cameron Gibson, Amber D Kohler , et al. · 2024

Pyoderma gangrenosum is a rare dermatologic disorder that disrupts the skin barrier, requiring immunosuppressive therapy. We successfully used cefiderocol for the treatment of an extensively drug-resistant Pseudomonas aeruginosa bacteremia…

Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study Open

Neil R. Aggarwal, Laurel Beaty, Tellen D. Bennett, Lindsey E. Fish, Jason R. Jacobs , et al. · 2024

U.S. National Institutes of Health.

Effectiveness of subcutaneous monoclonal antibody treatment in emergency department outpatients with COVID‐19 Open

Sarah K. Wendel, Adane F. Wogu, Nichole E. Carlson, Laurel Beaty, Tellen D. Bennett , et al. · 2024

Oritavancin as sequential therapy for Gram-positive bloodstream infections Open

Williams Monier Texidor, Matthew A. Miller, Kyle C. Molina, Martin Kršák, Barbara Calvert , et al. · 2024

Background Oritavancin, a long-acting lipoglycopeptide approved for use in acute bacterial skin and skin structure infections, has limited data evaluating use in serious infections due to Gram-positive organisms. We aimed to assess the eff…

Substance use disorder-associated infections’ treatment with dalbavancin enabling outpatient transition (SUDDEN OUT) – an investigator-initiated single-arm unblinded prospective cohort study Open

Martin Kršák, Sias Scherger, Matthew A. Miller, Vincent A. Cobb, Brian T. Montague , et al. · 2024

Background: Severe gram-positive infections are frequent in people who inject drugs, and successful completion of treatment presents unique challenges in this population. Objectives: We aimed to evaluate the feasibility of a long-acting an…

Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022 Open

Ashlan J. Kunz Coyne, Sara Alosaimy, Kristen Lucas, Abdalhamid M Lagnf, Taylor Morrisette , et al. · 2023

Eravacycline is a synthetic fluorocycline approved by the U.S. Food and Drug Administration in 2018. This study aimed to describe clinical and microbiological outcomes in addition to associated adverse effects of eravacycline used in U.S. …

2237. Outcomes of Metronidazole Dosed Every 12 Hours Versus Every 8 Hours Open

Maggie Box, Kelly Duong, Kyle C. Molina · 2023

Background Metronidazole (MTZ) is a mainstay treatment for anaerobic infections. Due to its pharmacokinetic and phamacodynamic properties, it can be dosed at 8 -, 12-, or 24-hour intervals. MTZ’s adverse effects depend on the cumulative do…

808. Outcomes of Invasive Candidiasis Stratified by Antifungal Therapy Open

Maggie Box, Lara Anwar, Kyle C. Molina · 2023

Background IDSA guidelines for invasive candidiasis recommend echinocandins (ECH) as first-line agents for initial therapy, with fluconazole (FLU) as an acceptable alternative. Transitioning from an ECH to FLU is also recommended in clinic…

Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes Open

Amer El Ghali, Taylor Morrisette, Sara Alosaimy, Kristen Lucas, Maria G. Tupayachi-Ortiz , et al. · 2023

Infections due to nontuberculous mycobacteria (NTM) continue to increase in prevalence, leading to problematic clinical outcomes. Omadacycline (OMC) is an aminomethylcycline antibiotic with FDA orphan drug and fast-track designations for p…

Oritavancin as Sequential Therapy for Gram-positive Bloodstream Infections Open

Williams Monier Texidor, Matthew A. Miller, Kyle C. Molina, Martin Kršák, Barbara Calvert , et al. · 2023

Background Oritavancin, a long-acting lipoglycopeptide approved for use in acute bacterial skin and skin structure infections, has limited data evaluating use in serious infections due to Gram-positive organisms. We aimed to assess the eff…

Augmented Renal Function in Burn Patients: Occurrence and Discordance With Commonly Used Methods to Assess Renal Function Open

Scott W. Mueller, Brittany Blass, Kyle C. Molina, Cameron Gibson, Martin Kršák , et al. · 2023

Augmented renal clearance (ARC) is defined by supraphysiologic renal function and is associated with drug failure due to subtherapeutic drug exposure. Burn patients are cited as being at high risk for ARC, yet rates of ARC have not been we…

Cytomegalovirus Immune reconstitution in cord blood transplant recipients on letermovir prophylaxis Open

Maheen Z. Abidi, Kyle C. Molina, Krystle Garth, Jonathan A. Gutman, Adriana Weinberg · 2023

Introduction Cytomegalovirus (CMV) can cause significant morbidity and mortality in cord blood transplant (CBT) recipients. Development of CMV‐specific cell‐mediated immunity (CMV‐CMI) has been associated with protection against CMV clinic…

Response to Mahatanan and Kang: It's Complicated Open

Kyle C. Molina, Scott W. Mueller, Matthew A. Miller, Martin Kršák · 2023

Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5 Open

Kyle C. Molina, Victoria Kennerley, Laurel Beaty, Tellen D. Bennett, Nichole E. Carlson , et al. · 2023

During the Omicron BA.2/BA.2.12.1/BA.4/BA.5 variant phase, bebtelovimab was associated with lower hospitalization.

Best Practices in the Management of Infectious Complications for Patients With Cancer: Management of Febrile Neutropenia Open

Kyle C. Molina · 2023

Managing infection in patients with neutropenia is a difficult challenge, as fever is often the only clinical symptom. At JADPRO Live 2022, Kyle C. Molina, PharmD, BCIDP, AAVHIP, of the University of Colorado Hospital, discussed the epidem…

Real-world use of nirmatrelvir–ritonavir: who benefits? Open

Kyle C. Molina, Adit A. Ginde · 2023

Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study Open

Neil Krishan Aggarwal, Kyle C. Molina, Laurel Beaty, Tellen D. Bennett, Nichole E. Carlson , et al. · 2023

Previous corticosteroid exposure associates with an increased Pneumocystis jirovecii pneumonia mortality among HIV-negative patients: a global research network with a follow-up multicenter case-control study Open

Lilian Vargas Barahona, Kyle C. Molina, Laura Pedraza, Stefan Sillau, Alex Tagawa , et al. · 2023

Background: HIV-negative patients have substantial mortality from Pneumocystis jirovecii pneumonia (PJP). We lack predictors of HIV-negative PJP-associated mortality. Objective: We aim to characterize the role of prior corticosteroid expos…

1422. A Multi-Center Evaluation of Omadacycline for Multi-Drug Resistant Infections Open

Amer El Ghali, Amer El Ghali, Sara Allosaimy, Taylor Morrisette, Kyle C. Molina , et al. · 2022

Background Multi-drug resistant (MDR) pathogens are a continuously evolving threat for which there are limited effective treatment modalities. Omadacycline (OMC) is a novel oral and intravenously administered aminomethylcycline with potent…

633. Eravacycline Use in Immunocompromised Patients: Multicenter Evaluation of Clinical and Safety Endpoints Open

Ashlan J. Kunz Coyne, Sara Allosaimy, Kyle C. Molina, Lena Kang-Birken, Abdalhamid M Lagnf , et al. · 2022

Background Infections caused by multidrug-resistant (MDR) bacteria are an increasingly common public health threat associated with worse outcomes in immunocompromised patients. Eravacycline (ERV) has potent in-vitro activity against MDR Gr…

Kyle C. Molina YOU? Author Swipe